BackEli Lilly and Company Overview

Eli Lilly and Company EBIT

Eli Lilly and Company's EBIT is $40B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$13.38B
↑ 85.04% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$39.72B
↑ 71.03% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Eli Lilly and Company (LLY.TO) FAQ

The latest EBIT for LLY.TO is $40B as of September 2026. That compares with $23B in the prior-year period — up 71.0% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Eli Lilly and Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, LLY.TO's EBIT moved from $23B to $40B — a 71.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eli Lilly and Company's operating scale or balance-sheet position.

Against Healthcare companies, LLY.TO currently prints $40B for EBIT, while the sector average sits near $1.9T. That is roughly 98.0% below the sector mean. Large gaps often invite a closer look at Eli Lilly and Company's growth, margins, and balance sheet.

A EBIT figure of $40B for LLY.TO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting LLY.TO's EBIT ($40B), review year-over-year change from $23B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers